Inspire Q2 2026 Earnings: Revenue Falls as Gross Margin Expands

Inspire Medical Systems (NYSE: INSP) reported Q2 2026 revenue of $200.6 million, down 7.6% from $217.1 million a year earlier, while diluted EPS improved to $0.01 from a loss of $0.12. U.S. coding and reimbursement changes pressured sales, but a richer Inspire V product mix lifted gross margin and working-capital improvements raised operating cash flow to $23.2 million. The results cover the quarter ended June 30, 2026, and were released on August 3.

Core Financial Results

The U.S. revenue decline outweighed international growth, causing total revenue and gross profit to fall. Gross profit declined less than revenue because gross margin expanded 150 basis points to 85.5%, primarily due to the higher-margin Inspire V system representing a larger share of sales.

Operating expenses decreased 7.4% to $172.0 million, reflecting lower stock-based compensation and marketing expenses. This helped narrow the GAAP operating loss, although adjusted operating income and adjusted EPS were lower than a year earlier.

Adjusted operating income, adjusted EPS and adjusted EBITDA are non-GAAP measures. Q2 2026 adjustments included $3.7 million of legal expenses and the tax impact of stock-based compensation.

Business and Geographic Performance

U.S. revenue was the principal source of the consolidated decline. Inspire attributed the weakness primarily to an evolving coding and reimbursement environment, which continued to affect customers and the adoption process. International revenue increased and partially offset the U.S. contraction, although the company did not provide a numerical regional breakdown.

Product mix provided an important offset to lower sales. Increased sales of the Inspire V system, which carries a higher gross margin than Inspire IV, drove the 150-basis-point expansion in consolidated gross margin.

Profitability, Cash Flow and the Balance Sheet

GAAP profitability improved while underlying adjusted earnings weakened. The difference partly reflects unusually high accelerated stock-based compensation in Q2 2025 and a $4.0 million prior-year impairment charge. Excluding adjustment items, operating income fell to $3.2 million from $9.6 million, and adjusted operating margin contracted to 1.6% from 4.4%.

The effective tax rate increased to 89.9%, mainly because of a tax shortfall related to stock-based compensation. This limited GAAP net earnings despite positive pre-tax income. Adjusted net earnings declined to $4.0 million from $10.1 million.

Cash generation moved in the opposite direction from adjusted earnings. Operating cash flow increased to $23.2 million from $2.7 million, with management citing improved working capital in receivables and inventories. Cash, cash equivalents and investments totaled $415.2 million at June 30, up $10.6 million from December 31, 2025. Over the same period, accounts receivable decreased to $103.3 million from $119.7 million, while inventory increased to $170.5 million from $145.3 million.

Project Horizon Creates Investment Capacity but Adds Near-Term Charges

Inspire introduced Project Horizon to align resources with revenue initiatives, streamline the organization and consolidate production. The company expects the plan to create approximately $30 million of annualized growth investment capacity, which it intends to redeploy into initiatives designed to accelerate revenue growth. Because the capacity is expected to be reinvested, it should not be read as a stated $30 million increase in earnings.

The first phase is expected to produce $20 million to $25 million of pre-tax restructuring charges. That total includes approximately $4 million to $5 million of employee-related costs and $16 million to $20 million of other expenses expected to be non-cash. Most actions are scheduled for completion during Q3, with the overall program expected to be substantially complete by the end of 2026.

Full-Year 2026 Guidance

Inspire raised its previously announced revenue outlook to $835 million to $875 million. The company also provided profitability, tax and capital-spending assumptions that incorporate the expected effects of Project Horizon and stock-based compensation.

The gap between GAAP and adjusted EPS reflects expected legal expenses, Project Horizon restructuring charges and the estimated tax impact of stock-based compensation. The full-year adjusted operating margin target also stands above the 1.6% recorded in Q2, making margin delivery an important metric in subsequent results.

Recent Insider Transactions

The supplied six-month insider summary classified 231,236 shares across 24 transactions as purchases and 14,037 shares across four transactions as sales, producing net reported purchases of 217,199 shares. However, the latest records are dominated by zero-price stock awards rather than disclosed open-market purchases, so the aggregate should not be interpreted as purely discretionary buying.

The source did not provide the number of shares attached to the individual stock awards. A reported transaction price of zero identifies the grants’ recorded price and does not establish that the awards had no economic value.

Risks Investors Need to Watch

• Coding and reimbursement pressure: The changing U.S. environment was the main reason quarterly revenue declined. Continued disruption could weigh on procedure volumes and adoption of Inspire therapy.
• Adjusted profitability: Despite lower operating expenses and improved GAAP results, adjusted operating margin fell to 1.6% and adjusted EPS declined 58.8%. Revenue stabilization will be important for delivering the full-year margin range.
• Project Horizon execution: Inspire expects $20 million to $25 million of restructuring charges, while the intended $30 million of annualized investment capacity depends on successful implementation and redeployment.
• Tax volatility: Stock-based compensation produced a tax shortfall and an 89.9% quarterly effective tax rate. Full-year guidance assumes a GAAP effective rate of approximately 95% to 100%.
• Inventory management: Inventory increased to $170.5 million from $145.3 million at year-end while quarterly revenue declined year over year, increasing the importance of matching supply with demand.

Summary

Inspire’s Q2 2026 results combined U.S.-led revenue pressure with better product mix, lower reported expenses and substantially stronger operating cash flow. Gross margin expanded and GAAP results improved, but adjusted operating income, adjusted EPS and adjusted EBITDA declined. The next areas to monitor are the U.S. coding and reimbursement environment, progress toward the raised revenue outlook, adjusted-margin delivery and whether Project Horizon creates the planned investment capacity without adding execution problems.